With investments of approximately one billion euros, Japan headquartered Daiichi Sankyo will expand its production and development site in Pfaffenhofen an der Ilm, north of Munich, into an international innovation centre.

At least 350 new jobs will be created by 2030, including numerous positions for top international researchers, process engineers and other specialists in sterile and biotechnology.

In addition to more production capacities in the area of cardiovascular diseases, new laboratories will be created, particularly for antibody drug conjugate (ADC) technology. In the future, novel cancer therapies against, among other things, breast, lung and stomach cancer will be developed and manufactured in Pfaffenhofen.

The Pfaffenhofen production site has stood for the highest quality standards for more than 60 years. The medicines produced at the factory are shipped to more than 50 countries worldwide. Pharmaceutical development is also already taking place at the site. In addition, Pfaffenhofen is one of Daiichi Sankyo's largest sites in the world for the production of clinical products.

One of the elements of the investment is the new building for Daiichi Sankyo's ADC, which is scheduled to be completed by the end of 2026.

In addition to the areas of production and research, the investments also strengthen quality assurance and logistics. Renewable energies will play an increasingly important role: the plant already relies on wind, water, biomass and solar energy, which it generates itself either with its own systems or in cooperation with local partners.